Fredag 10 Oktober | 19:55:40 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2025-11-27 11:00 Kvartalsrapport 2025-Q3
2025-08-28 - Kvartalsrapport 2025-Q2
2025-05-28 - Kvartalsrapport 2025-Q1
2025-05-09 - X-dag ordinarie utdelning POLAR 0.00 SEK
2025-05-08 - Årsstämma
2025-02-27 - Bokslutskommuniké 2024
2025-02-20 - Extra Bolagsstämma 2024
2024-12-05 - Split POLAR 300:1
2024-11-29 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-05-31 - Kvartalsrapport 2024-Q1
2024-05-29 - X-dag ordinarie utdelning POLAR 0.00 SEK
2024-05-28 - Årsstämma
2024-02-23 - Bokslutskommuniké 2023
2023-11-24 - Kvartalsrapport 2023-Q3
2023-09-08 - Extra Bolagsstämma 2023
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-26 - Kvartalsrapport 2023-Q1
2023-05-17 - Årsstämma
2023-05-05 - X-dag ordinarie utdelning POLAR 0.00 SEK
2023-03-13 - Extra Bolagsstämma 2022
2023-02-24 - Bokslutskommuniké 2022
2022-11-25 - Kvartalsrapport 2022-Q3
2022-08-26 - Kvartalsrapport 2022-Q2
2022-05-27 - Kvartalsrapport 2022-Q1
2022-05-06 - X-dag ordinarie utdelning POLAR 0.00 SEK
2022-05-05 - Årsstämma
2022-02-25 - Bokslutskommuniké 2021
2021-11-26 - Kvartalsrapport 2021-Q3
2021-08-27 - Kvartalsrapport 2021-Q2
2021-05-28 - Kvartalsrapport 2021-Q1
2021-05-06 - X-dag ordinarie utdelning POLAR 0.00 SEK
2021-05-05 - Årsstämma
2021-02-26 - Bokslutskommuniké 2020
2020-11-27 - Kvartalsrapport 2020-Q3
2020-08-28 - Kvartalsrapport 2020-Q2
2020-07-01 - X-dag ordinarie utdelning POLAR 0.00 SEK
2020-06-30 - Årsstämma
2020-05-29 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2020-02-14 - Extra Bolagsstämma 2020
2019-10-23 - Kvartalsrapport 2019-Q3
2019-07-24 - Kvartalsrapport 2019-Q2
2019-05-07 - Split POLAR 16:1
2019-04-26 - Kvartalsrapport 2019-Q1
2019-03-19 - Årsstämma
2019-02-04 - X-dag ordinarie utdelning POLAR 0.00 SEK
2019-02-01 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
PolarCool är verksamt inom medicinteknik. Bolaget är inriktade mot produkter och lösningar för skador, främst huvudskador, från sport och aktivitet. Störst fokus återfinns inom forskning och utveckling av produkter som används vid behandling av hjärnskador, där lösningarna används av idrottsföreningar, vårdinrättningar och professionella organisationer. PolarCool grundades 2017 och innehas på global nivå, med störst närvaro inom den europeiska marknaden.
2025-10-07 10:01:00

PolarCool AB (publ.) announces that the COOLHEAD study (Clinical Observed Outcomes with Local Head-cooling After Diagnosed Concussions) has now officially commenced. The research study is using PolarCap® in professional rugby as an innovative treatment for sport-related concussions (SRC).

 

The study is being conducted at the highest level of rugby in a unique collaboration between PolarCool and three of the sport's most influential organizations: the two leagues United Rugby Championship* (URC) and Premiership Rugby** (PREM), as well as World Rugby, the international governing body for rugby union - the most globally widespread form of the game.

 

The study protocol for the COOLHEAD study has been published in the British Medical Journal Open Sport & Exercise Medicine (BOSEM). The aim of the study is to confirm the clinical effects of PolarCap® in professional rugby, building on previously published clinical studies in elite ice hockey that demonstrated improved recovery, reduced initial symptoms, and-most importantly-a significantly reduced risk of long-term absence among players treated with PolarCap®, compared to those receiving standard care alone. Rugby is a sport with a high incidence of concussions and well-structured medical routines, making it an ideal environment for such a study.

 

The study is being conducted across two groups:

 

  • United Rugby Championship (URC) - Intervention group: Immediate treatment (45 minutes of cooling) with PolarCap® within 30 minutes of concussion diagnosis, followed by World Rugby's standardized return-to-play protocol. Data collection is already underway in this group.
  • Premiership Rugby (PREM) - Control group: Standard concussion care only.

 

The study, being ran and evaluated independently by academics in Leeds Becket University, will track 100 concussions per cohort over two seasons, measuring outcomes such as: Return to play, symptom burden, cognitive and balance function, and player and medical staff experiences (qualitative interviews).

 

Erik Andersson, CEO of PolarCool AB, comments:

 

-We are proud to support the COOLHEAD study, which represents a major step forward in advancing evidence-based treatment for concussions. Our collaboration with URC, Premiership Rugby and World Rugby highlights the growing trust in our technology and of our shared ambition to deliver real benefits for athletes worldwide.

 

The COOLHEAD study represents the first large-scale evaluation of head and neck cooling in rugby. The results may influence the future management of concussions globally and strengthen PolarCool's position as a leader in evidence-based sports medicine innovation

 

* URC = multinational rugby union league with teams in Europe and South Africa.
** Premiership Rugby = England's top division for rugby union club teams.

 

For more information

Erik Andersson - CEO PolarCool AB (publ.) 
+46 - 73 860 57 00    
E-mail: erik.andersson@polarcool.se

 

About PolarCool AB (publ.)

PolarCool AB (publ.) is a medical device company that develops, markets, and sells products for sports medicine. The company focuses on treatment of concussive and sub-concussive brain injury with the portable cooling device PolarCap®. PolarCool AB (publ.) is based in Lund, Sweden, and its shares are listed on Spotlight Stock Market.